Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M E Gleave

Showing results (11-20 of 85) with videos related to

Pageof 9
Sort By:
Japanese Journal of Cancer Research : Gann|November 21, 2001
Introduction of clusterin gene into human renal cell carcinoma cells enhances their resistance to cytotoxic chemotherapy through inhibition of apoptosis both in vitro and in vivoI Hara, H Miyake, M E Gleave, et al.
Oncogene|March 30, 2026
Editorial Expression of Concern: GRP78 regulates clusterin stability, retrotranslocation and mitochondrial localization under ER stress in prostate cancerN Li, A Zoubeidi, E Beraldi, et al.
Journal of Vascular Surgery|August 7, 1999
In situ replacement of the aorta in a contaminated field with the infrarenal inferior vena cavaA C Ting, M E Gleave, Y N Hsiang
Oncogene|June 13, 2012
GRP78 regulates clusterin stability, retrotranslocation and mitochondrial localization under ER stress in prostate cancerN Li, A Zoubeidi, E Beraldi, et al.
Cancer Research|July 23, 1999
Castration-induced apoptosis of androgen-dependent shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteinsT Nickerson, H Miyake, M E Gleave, et al.
British Journal of Cancer|December 3, 2024
Editorial Expression of Concern: Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma modelY Kususda, H Miyake, M E Gleave, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|May 11, 2013
The future of systemic therapies for localised prostate cancerB J Eigl, M E Gleave, K N Chi
International Journal of Urology : Official Journal of the Japanese Urological Association|July 10, 2001
Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting anti-apoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivityH Miyake, I Hara, S Kamidono, et al.
Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology|November 25, 2006
The best local therapy for unfavorable risk prostate cancer: the role of surgeryR C Studd, R D Sowery, M E Gleave
British Journal of Cancer|May 17, 2012
Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma modelY Kususda, H Miyake, M E Gleave, et al.
Pageof 9

Showing results (11-20 of 85) with videos related to

Sort By:
Pageof 9
Japanese Journal of Cancer Research : Gann|November 21, 2001
Introduction of clusterin gene into human renal cell carcinoma cells enhances their resistance to cytotoxic chemotherapy through inhibition of apoptosis both in vitro and in vivoI Hara, H Miyake, M E Gleave, et al.
Oncogene|March 30, 2026
Editorial Expression of Concern: GRP78 regulates clusterin stability, retrotranslocation and mitochondrial localization under ER stress in prostate cancerN Li, A Zoubeidi, E Beraldi, et al.
Journal of Vascular Surgery|August 7, 1999
In situ replacement of the aorta in a contaminated field with the infrarenal inferior vena cavaA C Ting, M E Gleave, Y N Hsiang
Oncogene|June 13, 2012
GRP78 regulates clusterin stability, retrotranslocation and mitochondrial localization under ER stress in prostate cancerN Li, A Zoubeidi, E Beraldi, et al.
Cancer Research|July 23, 1999
Castration-induced apoptosis of androgen-dependent shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteinsT Nickerson, H Miyake, M E Gleave, et al.
British Journal of Cancer|December 3, 2024
Editorial Expression of Concern: Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma modelY Kususda, H Miyake, M E Gleave, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|May 11, 2013
The future of systemic therapies for localised prostate cancerB J Eigl, M E Gleave, K N Chi
International Journal of Urology : Official Journal of the Japanese Urological Association|July 10, 2001
Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting anti-apoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivityH Miyake, I Hara, S Kamidono, et al.
Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology|November 25, 2006
The best local therapy for unfavorable risk prostate cancer: the role of surgeryR C Studd, R D Sowery, M E Gleave
British Journal of Cancer|May 17, 2012
Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma modelY Kususda, H Miyake, M E Gleave, et al.
Pageof 9